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A 42-year-old man presented with hypertension and proteinuria 22
years ago and was found to have adult polycystic kidney disease.
Within 8 years he was approaching end-stage renal failure (creatinine
clearance, 10 mI/mm). The hemoglobin (Hb) was 10.0 g/dl. Hemodial-
ysis was initiated 13 years ago, when his Hb was 6.6 g/dl. Two months
later, it had risen spontaneously to 10.0 g/dl. The serum erythropoietin
was 20 lU/liter. A left nephrectomy was performed to make space for a
renal transplant. The Hb was 9.7 gIdl preoperatively and fell to 8.7 g/dl
in the first postoperative month. He had two unsuccessful renal
transplants, one 12 years ago and one 10 years ago. Nine years ago, his
remaining polycystic kidney became infected and had to be removed.
He became dependent on blood transfusions and received a total of 80
units over the subsequent 3 years. Six years ago, he was enrolled in a
trial of recombinant human erythropoietin. His Hb was 6.2 gldl; red cell
mass, 6.7 ml/kg (normal, 25—35 mI/kg); serum erythropoietin, 7.3
LU/liter; erythron transferrin uptake (ETU), 24 mol iron/liter whole
blood/day (normal, 60 12); and absolute reticulocytes 23 x 109/liter.
The white blood cell count was 4.5 x 109/liter and platelet count was
171 x l09/liter. At a dose of 96 lU/kg given intravenously 3 times
weekly, his Hb rose to 11.9 gldl over 10 weeks; the red cell mass rose
to 18.4 ml/kg, the ETU to 116 smol/liter whole blood/day, and the
absolute reticulocytes to 206 x l09/liter. The white blood cell and
platelet counts were unchanged at 4.2 x 109/liter and 168 x 109/liter.
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Radcliffe Hospital, Oxford, England): In addition to providing
the means for producing recombinant erythropoietin for clinical
use, molecular cloning of the erythropoietin gene [1—5] has
provided a new impetus for studying the biology of erythropoi-
etin and the control of erythropoiesis. The use of recombinant
erythropoietin in the treatment of anemia of chronic renal
failure was discussed in a Nephrology Forum by Dr. J. W.
Eschbach [6]; here I would like to focus on some of the recent
advances in our understanding of the basic biology of this system.
Erythropoietin is unique among the hemopoietic growth
factors in functioning, at least in the adult, as a blood stream
hormone. Important insights into the regulation of erythropoi
etin and erythrOpoiesis can, therefore, be gained from measure-
ments of the serum erythropoietin level in health and disease. I
will begin by commenting on some of these observations.
People without renal disease have an approximately inverse
linear relationship between hemoglobin and the logarithm of the
serum erythropoietin level (Fig. 1), with levels of erythropoietin
reaching several hundredfold above baseline at the lowest
levels of hemoglobin [7—10]. Many clinical and experimental
observations have demonstrated that not only anemia [7—11] but
reduced arterial P°2 [12—14] and increased hemoglobin affinity
[13—16] can stimulate erythropoietin production. These obser-
vations have led to the proposal that blood oxygen availability
rather than hematocrit or red cell mass per se is sensed and
suggest that the stimulus for erythropoietin production is low-
ered tissue oxygenation. Thus a homeostatic response is ef-
fected: a reduction in the hematocrit is corrected by hypoxic
stimulation of erythropoietin production and hence erythropoi-
esis [17].
The central importance of these responses in control of
erythropoiesis is demonstrated by the patient presented. After
the initial period of maintenance dialysis, his hemoglobin sta-
bilized in the range of 8—10 g/dl. His serum erythropoietin was
in the normal range, although in the setting of anemia, it was
somewhat below the level observed in anemias not associated
with renal disease. Just prior to starting dialysis, his anemia was
exacerbated; this phenomenon is well recognized [18]. In some
cases, overhydration is partly responsible, and in patients with
good cardiac function who are receiving antihypertensive med-
ication, the degree of overhydration is easily underestimated.
Unidentified uremic toxins could exacerbate the anemia of renal
disease [19, 20]. Such toxins might be removed in part when
maintenance dialysis begins [18], although significant doubt has
been cast on the specificity and hence pathophysiologic rele-
vance of in-vitro demonstrations of uremic erythropoietic in-
hibitors [6].
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Fig. 1. Esti,nates of immunoreactive erythropoietin in serum of normal
men (Li) and women () and of patients with hypopiastic anemia from
r'q/disease (•) and aplastic (0) or Fanconi's (0) anemias (From Ref.
10 with rrmission).
After hemodialysis was established, the patient maintained a
hemoglobin level that was somewhat higher than usual for
dialysis patients until he was rendered anephric. Erythropoietin
production by the polycystic kidneys was most probably re-
sponsible; erythropoietin levels in patients with polycystic
kidneys tend to be higher than erythropoietin levels in other
dialysis patients [21, 22], and in-situ hybridization studies have
localized erythropoietin mRNA in stroma cells of the cyst walls
[23].
After the second nephrectomy, the patient's anemia wors-
ened; severely reduced red cell mass, reticulocyte count, and
erythron transferrin uptake indicated a severe hypoplastic
state. The serum erythropoietin level was very low in relation to
what would be anticipated for the degree of anemia. Several
important points are illustrated: (1) The role of the kidney is
central in erythropoietin production. (2) Measurable serum
erythropoietin after bilateral nephrectomy indicates the exis-
tence of non-renal sources. (3) Low levels of erythropoietin,
similar to those in the normal basal state, appear to have a
major effect on erythropoiesis. (4) The response to exogenous
erythropoietin emphasizes the specific role of erythropoietin in
supporting erythropoiesis. When the patient was treated with
recombinant erythropoietin, all parameters of erythropoiesis
were dramatically increased and, despite the uremia, the patient
achieved a normal red cell mass. The slightly increased eryth-
ron transferrin uptake probably arose from the need to com-
pensate for a modestly increased red cell turnover.
Erythropoietin therefore appears to be essential for support-
ing erythropoiesis. In addition to providing a graded response to
varying degrees of hypoxia, regulated erythropoietin produc-
tion probably contributes to the maintenance of hematocrit near
the normal range. Several other observations support this view.
The erythropoietin receptor
Stimulation of erythropoiesis by erythropoietin involves in-
teraction with a specific receptor. The availability of recombi-
nant erythropoietin enabled D'Andrea and colleagues to isolate
a cDNA clone for the mouse erythropoietin receptor by expres-
sion cloning [32]. Cos cells, an SV4O virus-transformed kidney
fibroblastoid cell line, were transfected with cDNA prepared
from erythropoietin receptor expressing mouse erythroleuke-
mia cells; the transfected cells then were screened for expres-
sion of the erythropoietin receptor with radioiodinated erythro-
poietin. The erythropoietin receptor cDNA was recovered from
positive transfectants [32]. Isolation of hUman clones for the
erythropoietin receptor has subsequently been reported [33,
34]. The availability of cloned genes for both erythropoietin and
its receptor has allowed detailed studies of this molecular
interaction and the consequent stimulation of erythropoiesis.
These studies demonstrate important homologies with molecu-
lar and functional aspects of other growth control systems.
The mouse erythropoietin receptor cDNA codes for a 507
amino acid polypeptide with a single membrane-spanning do-
main [32]. The extracellular N-terminal region contains the
erythropoietin-binding domain, and the C-terminal intracellular
domain is associated with signal transduction [32]. Significant
sequence homologies have been found with other growth factor
receptors, including hemopoietic cytokine receptors for
G-CSF, GM-CSF, 11-2, 11-3, 11-4, 11-5, 11-6, 11-7, and receptors
for other growth-related molecules such as growth hormone and
prolactin [31, 35—39]. Hence, it is now recognized that the
erythropoietin receptor is a member of a large superfamily of
receptors. More distant homologies have been recognized with
interferon receptors [40] and with the type-Ill domain of the
cell-adhesion protein fibronectin [41]. Bazan proposed that
these molecules have evolved from primitive adhesive mole-
cules to their present role as receptors for specific proteins [38].
Recognition of homology in part depends on the existence of
characteristic motifs (Fig. 2). For instance, in the N-terminal
extracellular ligand-binding domain, two distinctive motifs are
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This understanding derived from clinical physiology provides
200 ° ° an important background to the molecular analysis of control of
erythropoietin production and erythropoiesis. First, erythropoi-
etin is seen to be more than a permissive survival factor; rather,
50 it acts as a growth regulator over an unusually large dynamic
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range. Second, tissue hypoxia is identified as a major error
signal in the feedback loop. Third, in contrast with many
hematopoietic growth factors [31], redundancy is limited, and
10 ° an absolute requirement for erythropoietin exists. Against this
background I would like to discuss some recent advances in our
understanding of how erythropoietin promotes erythropoiesis,
and how the production of erythropoietin is regulated by blood
oxygen availability.
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Fig. 2. Structural and functional homologies among different growth
factor receptors. Homologous domains of the cytokine receptors
EPO-R, IL-2R/3, and IL-3R are aligned. The extracellular domains
share a highly similar 20-amino acid sequence, which includes a
conserved Trp-Ser-X-Trp-Ser motif (black box). The four conserved
cysteine residues (Cl—C4) are also aligned. The homologous external
domain is duplicated in the IL-3R (regions I and II). The cytoplasmic
domain of these three receptors contains a conserved region rich in
proline, serine, and acidic residues (cross-hatched bars) (From Ref. 35).
seen: 2 pairs of cysteine residues near the N-terminus and a
Trp-Ser-X-Trp-Ser sequence lying just outside the membrane-
spanning domain [35]. If these motifs have indeed been con-
served during evolution from a common ancestral gene, they
probably are of key functional significance. Experimental site-
directed mutagenesis has shown this to be the case. Two groups
recently reported that mutations in the Trp-Ser-X-Trp-Ser
motifs do destroy the function of the erythropoietin receptor
[42, 43]. For instance, one study showed that when mutations
were made in this motif, the mutant receptor polypeptide was
not processed correctly, and it could not bind erythropoietin
[43]. Furthermore, when introduced into an erythropoietin
receptor with a pre-existing mutation conveying constitutive
activation [44], mutations of the Trp-Ser-X-Trp-Ser motif elim-
inated cellular activation [43].
Homology in the ligand-binding domains of this receptor
superfamily raises the question as to whether the ligands
themselves contain significant homologies. Bazan postulated
that, although important similarities are difficult to discern from
the primary amino acid structure, they do exist [39]. The ligands
are rich in sequences that are predicted to form a helices and
can be modeled to form a bundle of 4 antiparallel helices, a
structure that has been demonstrated crystallographically for
growth hormone [45]. Site-directed niutagenesis studies and
antibody-blocking studies are consistent with such a model for
the structure of erythropoietin [46—48], although these studies
cannot prove the structure. In the case of growth hormone, the
crystal structure of the ligand-receptor complex has recently
been obtained [49, 50] and the molecular basis of this type of
ligand-receptor interaction soon may be determined precisely.
These receptors also have important similarities in their
mechanisms of cell activation. Tyrosine kinase activity is
Fig. 3. Erythropoietin-dependent proliferation of the transfected
mouse pro-B cell line LyD9. O.D. refers to the optical density of the
colorimetric MTT (tetrazolium) assay used to measure cell prolifera-
tion. Untransfected cells did not proliferate in response to erythropoi-
etin (squares). In contrast, transfectants expressing the erythropoietin
receptor showed dose-dependent proliferation in response to erythro-
poietin (open circles), which resembled the response to IL-3 (closed
circles). In further experiments, erythropoietin receptors bearing mu-
tations in the Trp-Ser-X-Trp-Ser motif were found to be inactive in this
system (From Ref. 42).
associated with growth control systems, in that most of the
known tyrosine kinases are either growth-factor receptors or
proto-oncogenes involved in growth regulation [51]. Activation
of the erythropoietin receptor is followed rapidly by tyrosine
phosphorylation of a set of proteins that includes the receptor
itself [52—55]. No enzymatic activities are predicted from anal-
ysis of the sequence of the cloned gene for the erythropoietin
receptor [35], and this molecule is probably non-covalently
associated with other proteins possessing tyrosine kinase activ-
ity. This possibility would conform with cross-linking studies
that consistently link erythropoietin to a complex that is bigger
than that predicted from the sequence of the cloned erythropoi-
etin receptor gene [35, 56—58]. Such a mechanism is similar to
that proposed for other members of this receptor family, such
as the interleukin-2 receptor [59].
Transfection experiments with the erythropoietin receptor
provide a striking demonstration of the receptor's ability to
interact with common cell activation mechanisms [42, 60, 61].
For instance, after transfection of the 11-3-dependent pro-B cell
line LyD9 with the erythropoietin receptor, the cell line be-
comes erythropoietin responsive and 11-3 can be substituted by
erythropoietin in the culture medium [42] (Fig. 3). Although this
phenomenon is demonstrable in other cells, the interactive
mechanisms do not appear to be universal; although expression
of the receptor in Cos cell transfectants permitted ligand
binding, this binding did not alter cell growth [32].
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Given functional overlap with growth control mechanisms in
other cells, the specific dependence of erythropoiesis on eryth-
ropoietin must arise from controlled expression of the erythro-
poietin receptor and specific liganding by erythropoietin. This
dependence is clearly indicated by the parallel development of
erythropoietin dependence and expression of the erythropoietin
receptor in cultured marrow cells. Thus the appearance of
substantial erythropoietin receptor expression in erythroid pro-
genitor cells (BFU-E: burst-forming units-erythroid) correlates
with the onset of erythropoietin dependency. Later erythroid
progenitors (CFU-E: colony forming units-erythroid), which
demonstrate striking erythropoietin-dependent responses, ex-
press the erythropoietin receptor most abundantly [57, 621.
One important insight into how expression of the erythropoi-
etin receptor is controlled during erythroid differentiation has
come from the identification and molecular cloning of the gene
for the erythroid transcription factor GATA- 1 163—65], a nude-
oprotein that controls gene transcription in erythroid cells and
that is so named because it binds the DNA motif Tj (GATA)
A/G This motif was first recognized in control sequences
regulating globin gene expression, but it subsequently has been
found in many erythroid genes with diverse functions, including
the heme synthetic enzyme porphobilinogen deaminase, the
membrane protein glycophorin, and the erythropoietin receptor
[65]. Proof of the central importance of GATA- 1 in erythroid
differentiation has been obtained by targeted mutation of the
GATA-l gene. The X-linked GATA-l gene was disrupted in
male (XY) embryonic stem cells, and the cells were introduced
into mouse embryos at the blastocyst stage. Examination of the
resultant chimeric mice revealed that the mutant stem cells
contributed to all differentiated tissues except erythroid tissues.
This study thus demonstrated that GATA- 1 is essential for
erythroid development [66]. Co-transfection experiments have
shown that GATA-l plays a dominant role in direct control of
erythropoietin receptor expression through interaction with a
GATA motif in the erythropoietin receptor gene promoter [67,
68]. Furthermore, binding of erythropoietin to the erythropoi-
etin receptor up-regulates expression of GATA-l, thus poten-
tially reinforcing the cell's commitment to erythroid differenti-
ation [68].
The interaction between the erythropoietin receptor and
GATA- 1 provides some insight as to how a tissue-specific
transcription factor interacts with a growth iactor receptor to
control differentiated growth. Clearly much remains unex-
plained, particularly the early events in progenitor cells, which
regulate initial expression of GATA- 1. What I would like to
emphasize is that erythropoietin plays a central role in growth
control of the erythron, using mechanisms that appear to
operate in a wide variety of settings.
Regulation of erythropoietin
As I said, an unusual feature of the erythropoietin/erythro-
poiesis growth control system is that the error signal indicating
inadequate growth has been clearly defined. Reduced tissue
oxygenation signals the existence of an inadequate erythron,
and leads to production of erythropoietin. I would therefore
now like to consider the mechanism by which blood oxygen
availability regulates serum erythropoietin. To understand this
mechanism, we first must consider the sites of erythropoietin
production and oxygen sensing; second, what determines tissue
oxygenation at these sites; and third, the mechanisms of signal
reception and of induction of gene expression.
Changes in serum erythropoietin levels appear to depend
largely or entirely on changes in hormone production rate
[69—71]. Moreover, in response to stimulation, increases in
serum erythropoietin levels are paralleled by changes in the
abundance of erythropoietin mRNA. These changes indicate
that the level of erythropoietin mRNA is the major determinant
of hormone production rate [72—74]. Studies of the organ
distribution of erythropoietin mRNA [75, 76] have confirmed
the results of the classical organ ablation studies which demon-
strated, in adults, that the kidney is the major organ responsible
for erythropoietin production [77] but that the liver is capable of
significant erythropoietin production as well [13, 78].
More sensitive methods for detection of erythropoietin
mRNA also have demonstrated small quantities of erythropoi-
etin mRNA in testis, brain, lung, and spleen of rodents [74, 79].
In anemic or hypoxically stimulated animals, these tissues
harbor amounts of erythropoietin mRNA that are insignificant
in comparison to the large amounts found in kidney and liver
[74], and their physiologic role is uncertain.
Even after bilateral nephrectomy, the patient presented here
had detectable circulating erythropoietin. Organ ablation stud-
ies in animals have indicated that the highest serum erythropoi-
etin level achievable after bilateral nephrectomy is only 10% to
20% of the level achievable normally, and that the liver is the
site of production under these circumstances [13, 77, 78, 80]. A
sustained level of this magnitude should be sufficient to correct
the anemia of renal disease, yet clearly this does not happen.
Using RNase protection assays to obtain a quantitative assess-
ment of the total erythropoietin mRNA, my colleagues and I
examined hepatic erythropoietin mRNA regulation in the rat.
During very severe stimulation by anemia or hypoxia, hepatic
erythropoietin mRNA accounts for 30% to 40% of the total
body content; it is possible, therefore, that the organ ablation
studies have underestimated hepatic erythropoietin production
[73, 74]. This hepatic potential for erythropoietin mRNA syn-
thesis was retained in rats rendered uremic by subtotal nephrec-
tomy, even though, as in humans, hepatic erythropoietin pro-
duction cannot support a normal hematocrit [79]. One possible
explanation for this apparent paradox is that hepatic erythro-
poietin mRNA is inefficiently translated, but a more interesting
explanation might lie in the different sensitivity of the organs to
hypoxic stimuli. Examination of the separate responses of
hepatic and renal erythropoietin mRNA in the rat to graded
degrees of hypoxia or anemia indicate that both organs made
some response even to mild stimulation, but that the quantita-
tive characteristics of the response were different: the liver
responded less well to mild stimulation than did the kidney [74]
(Fig. 4). Thus, while the potential for hepatic erythropoietin
production is preserved in severe renal disease, failure of
anemia to be corrected might reflect different setting of the
hepatic feedback response. A similar unrealized potential for
erythropoietin production might be present in diseased kidneys.
Disturbance of the normally well-organized vascular anatomy
and reduced oxygen consumption arising from reduced trans-
port work in renal failure [81—84] might shift the renal feedback
response. Alternatively, local cytokine production [85, 861
might directly reduce erythropoietin gene expression. Studies
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Cellular site of erythropoietin formation
cells contain erythropoietin mRNA [90], and in renal adenocar-
cinomas that produce erythropoietin, the epithelial cells them-
selves appear to contain erythropoietin mRNA [91]. Neverthe-
less, two groups using the higher resolution provided by 35S
labeling of DNA and RNA probes have convincingly demon-
strated that erythropoietin mRNA is iroduced by cells lying
between the renal tubules [92, 93]. Consistent with this result is
the report by Eckardt and colleagues, who detected erythropoi-
etin mRNA in interstitial cells within cyst walls of polycystic
kidneys [23].
Two recent studies provide evidence that the source of renal
erythropoietin is most probably a population of interstitial
fibroblasts. Using a digoxigenin-labeled riboprobe, Bachmann
et a! observed co-localization of erythropoietin mRNA and
immunohistochemical staining of a renal interstitial population
with antibodies to 5' ectonucleotidase [94]. We obtained a
similar result using double immunohistochemical labeling of
renal tissue from transgenic mice bearing an erythropoietin-
SV4O T-antigen reporter transgene (I will return to this later).
Although 5' ectonucleotidase is present on many other cell
populations, a fibroblast-like cell population is strongly and
specifically positive within the renal interstitium [95, 96]. This
fibroblast cell population, therefore, is the likely source of renal
erythropoietin.
Of interest in relation to the regulation of erythropoietin
production is the distribution of erythropoietin-producing cells
within the kidney. In unstimulated rodent kidney, only occa-
sional cells in the deep cortex or outer stripe of outer medulla
are positive for erythropoietin mRNA. With increasing anemia,
clusters of positive cells increase in number and spread from
deeper cortical regions to superficial cortex [97]. In these
kidneys, cells appeared to express erythropoietin mRNA in an
all-or-none fashion; the major determinant of total renal eryth-
ropoietin mRNA was the number of positive cells [97]. Eryth-
40 ropoietin mRNA-producing cells are found within the cortical
labyrinth and are rarely found in the medullary rays [98].
Interestingly, interstitial expression of 5' ectonucleotidase is
also confined within the cortical labyrinth. Expression of this
antigen, although constitutive in mesangial cells and along the
brush border of proximal tubular cells, is induced by anemia in
these interstitial cells. As is the case with erythropoietin induc-
tion, the expression of 5' ectonucleotidase is found not only in
the deep but also in the superficial layers of the cortex as
anemia becomes increasingly severe [99, 100]. Whether the 5'
ectonucleotidase activity plays any role in the regulation of
erythropoietin is unknown, however, and differences exist in
the temporal and spatial pattern of expression between the two
molecules. First, the time course of induction of 5' ectonucle-
otidase following anemic stimulation is significantly slower than
that for erythropoietin [89, 99]. Second, whereas many eryth-
ropoietin mRNA-producing cells are observed in the outer
stripe of the outer medulla in anemic rodents [97], interstitial 5'
ectonucleotidase is very weakly expressed in the interstitium of
this region [95].
Since the lowest oxygen tension is in the renal medulla
[101—103], it is clear that local oxygen tension is not the sole
factor determining the distribution of erythropoietin-producing
cells. Although it is tempting to speculate that, within the
cortical labyrinth, progressive activation from deep to superfi-
cial regions reflects intrarenal oxygen gradients in anemia,
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Fig. 4. Stimulation of erythropoietin mRNA in the liver and kidneys of
rats subjected to acute hemorrhage (8 hr) with saline replacement. A
Increases in total organ erythropoietin mRNA with progressively more
severe anemia. Both organs show an exponential increase in erythro-
poietin mRNA with reduction in hematocrit. B Total hepatic erythro-
poietin mRNA as a proportion of the total (hepatic plus renal) erythro-
poietin mRNA. The hepatic contribution to the total is lower in less
severe anemia (From Ref. 74).
in dialysis patients subject to intercurrent hypoxic stress dem-
onstrate substantial increases in serum erythropoietin [87, 88]
and support the view that a potential for erythropoietin produc-
tion exists in many such patients, although it is not clear
whether the liver or the diseased kidneys are the source.
Using Northern blot analysis of RNA prepared from tubular
and glomerular fractions of partially disaggregated kidneys from
hypoxic rats, Schuster and colleagues found erythropoietin
mRNA in the tubular fraction but not in the glomerular fraction
[89]. This result has been confirmed by in-situ hybridization
studies of rodent kidneys. One study has concluded that tubular
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proof of this has not been obtained. Furthermore, since the
renal cells that produce erythropoietin have not yet been
studied in isolation, it is not clear whether they rely on intrinsic
or extrinsic sensing mechanisms.
In-situ hybridization studies in mouse liver have identified
two cell populations that produce erythropoietin [104, 105].
About 80% of cells detected were a subpopulation of hepato-
cytes; 20% had a non-epithelial morphology. In transgenic
animals that overexpress a human erythropoietin transgene in
hepatocytes, the distribution of erythropoietin mRNA was
clearly centrilobular [1041; this finding is in keeping with known
oxygen gradients within liver.
Intrarenal oxygenation
Experiments in isolated perfused kidneys, which exhibit
oxygen-regulated modulation of erythropoietin mRNA levels
[106] and of erythropoietin production [107, 108], demonstrate
that all the events necessary for detection of hypoxia and
production of erythropoietin can operate intrarenally, although
not necessarily in the same cell. At first sight, the kidney might
appear ill suited to playing a major role in hypoxic sensing.
Renal blood flow and oxygen supply greatly exceed metabolic
requirements, arteriovenous oxygen extraction being on the
order of only 15% under normal circumstances. But it has long
been appreciated that the kidney contains poorly oxygenated
regions despite its overall high blood flow [109, 110]. The
generation of intrarenal hypoxia has been considered in detail in
relation to the susceptibility of the kidney to hypoperfusion
injury [1031 and I will only consider it briefly here. Of major
importance is the countercurrent arrangement of renal blood
vessels, which allows for the shunting of oxygen directly from
arterial to venous limbs [110, 111]. This countercurrent ex-
change of oxygen is most marked in the renal medulla, where
hypoxia is extreme, but it also operates in the renal cortex [1121
and creates tissue P°2 levels still well below those observed in
the renal veins [102, 113]. Although the operation of such a
system in the organ principally responsible for sensing blood
oxygen availability is intriguing, the exact role of this system is
unclear.
In another respect, the kidney might appear especially well
suited to sensing reduction in blood oxygen content as distinct
from changes in organ perfusion. Transport work accounts for
the majority of renal oxygen consumption [81—83, 114]. Since
more than 95% of the glomerular filtrate is reabsorbed, it
follows that renal oxygen consumption should be closely deter-
mined by the glomerular filtration rate. Thus, parallel changes
in renal blood flow and glomerular filtration rate might not
disturb the balance of oxygen consumption and supply, and
these changes might enable the kidney to respond to the change
in blood oxygen availability arising from anemia without con-
founding effects from alterations in renal hemodynamics [115].
Some evidence that a reduction in tubular transport work might
reduce erythropoietin production has been provided by studies
in hypoxic mice of the effect of diuretic agents on erythropoietin
production [1161. Whereas agents acting on distal tubular trans-
port had no effect, acetazolamide reduced erythropoietin pro-
duction. Acetazolamide acts primarily on the proximal tubule;
it is thus of interest that the cells producing erythropoietin lie
adjacent to proximal tubules [92]. Furthermore, when isolated
kidneys are perfused with hyperoncotic bovine serum albumin
at concentrations sufficient to oppose hydrostatic forces and
prevent glomerular filtration, levels of erythropoietin mRNA
are lower than those in filtering perfused kidneys receiving
equivalent perfusate oxygen delivery [117]. In neither of these
experimental settings, however, were direct measurements of
intrarenal oxygen tension made, so it is not clear that improved
renal oxygenation was the reason for the reduced erythropoie-
tin production. Although failure of glomerular filtration in renal
disease theoretically could reduce oxygen consumption, and
hence reduce the hypoxic signals for erythropoietin production,
it seems likely that the pathogenesis of erythropoietin defi-
ciency is much more complex. It is striking that the intact
isolated perfused kidney produces erythropoietin in a physio-
logically regulated manner [106—108], but there is as yet no
convincing demonstration of erythropoietin production by an
anatomically disrupted renal preparation. This raises the possi-
bility that some aspect of intrarenal architecture is of key
importance for erythropoietin production.
The oxygen-sensing ,nechanism
Many attempts have been made to define the nature of the
oxygen sensor. Hypoxia cannot be mimicked by the application
of inhibitors of mitochondrial respiration. Thus experiments in
vivo [1181, in hepatoma cells [1191, and in isolated perfused
kidneys [120] have shown that neither cyanide nor other inhib-
itors of the respiratory chain stimulate erythropoietin produc-
tion. Failure of the erythropoietin gene to be activated in these
experiments does not reflect nonspecific damage; in all these
systems it is possible to observe stimulation by hypoxia in the
presence of toxic concentrations of cyanide. These experiments
suggest that the sensing system is distinct from cell stress
responses triggered by nonspecific damage, and make it less
likely that the hypoxic sensing system operates through meta-
bolic derangements such as an alteration of phosphorylation
potential and cellular redox potential, which would be expected
to characterize both exposure to hypoxia and application of
inhibitors of the respiratory chain [121].
Drawing from results of experiments which they performed
on hepatoma cells, Goldberg et al proposed that the oxygen
sensor is a specific heme protein that can bind reversibly to
molecular oxygen [1221 (Fig. 5). Their hypothesis is of consid-
erable interest because of the widespread operation of heme
and hemoproteins in oxygen-dependent regulatory processes in
lower organisms [123—125]. Goldberg an colleagues noted that
not only hypoxia, but cobalt, nickel, and manganese could
stimulate erythropoietin production in human hepatoma cells
and proposed that these ions could substitute for the ferrous ion
in a putative heme protein and lock it in the deoxy form. Several
experiments were performed that support this hypothesis. The
behavior of carbon monoxide was studied because it specifi-
cally binds ferrous heme proteins [126]. Exposure to carbon
monoxide greatly reduced the erythropoietin response to hy-
poxia but not to cobalt. This response, which argues against
nonspecific toxicity, would be consistent with liganding of
carbon monoxide to the ferrous heme protein, but not to cobalt
protoporphyrin. Finally, when hepatoma cells were incubated
with deferoxamine and 4,6-dioxoheptanoic acid to reduce heme
synthesis, erythropoietin production in response to hypoxia,
nickel, and cobalt also declined.
Although oxygen gradients exist within cells [127], there is no
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compelling reason for siting oxygen sensing in any particular
cellular location. It is thus plausible that oxygen could interact
directly with nuclear proteins to induce DNA binding, or that it
could modify proteins bound to DNA at the erythropoietin
locus to induce transcription of the erythropoietin gene. The
effects of cycloheximide, an inhibitor of protein synthesis,
suggest that this is not the case. In hepatoma cells, cyclohex-
imide blocks induction of erythropoietin gene expression [122].
It is difficult to exclude the possibility that some permissive
effect is being abrogated by cycloheximide or even that the
effect simply arises from toxicity. However, sensitivity of the
inducing system to cycloheximide would be compatible with the
requirement for new protein synthesis in a cascade of events
leading to erythropoietin gene expression.
Coordination of erythropoietin gene expression
The rapid, high-amplitude induction of gene expression by
such a fundamental physiologic stimulus as hypoxia has at-
Fig. 5. Model proposed by Goldberg, Bunn,
and colleagues for the oxygen sensor in
erythropoietin-producing cells. It is proposed
that the action of cobaltous ions in promoting
erythropoietin gene expression arises from
substitution for ferrous ions in the porphyrin
ring of a putative heme protein, thus
mimicking the de-oxy conformation. Carbon
monoxide is postulated to reduce the hypoxic
induction of gene expression by mimicking
oxygen in liganding the heme moiety (From
Ref. 191). See Ref. 122 for details.
tracted interest in the regulation of erythropoietin as an inter-
esting example of tissue-restricted and inducible gene expres-
sion. In the final part of this Forum, I would like to describe
some selected experiments that address this issue.
Control of gene expression involves very complex interac-
tions between DNA and nuclear proteins. A first step in
un&rstanding these mechanisms is the definition of cis-acting
elements, sequences that are located on the same DNA mole-
cule in the vicinity of the gene and that regulate gene transcrip-
tion by coordinating the DNA-protein, protein-protein, and
possibly DNA-DNA interactions [for review see 128, 129]. In
mRNA, cis-acting sequences also interact with proteins to
control splicing, transport, degradation, and rate of translation
[130, 131]. Studies of cis-acting sequences provide the basis for
identification and purification of the associated DNA- or RNA-
binding proteins that mediate interaction between the signal
transduction pathway and the gene [132, 133].
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Many approaches are possible for identifying cis-acting se-
quences, but a particular problem in the analysis of erythropoi-
etin gene expression has been posed by uncertainty about the
nature of the renal interstitial cell that produces erythropoietin,
and by the lack of a tissue culture cell line from this source.
Therefore, I would first like to describe experiments in trans-
genie mice that give clues as to the mechanism of tissue
restriction in erythropoietin gene expression [134—136]. Intro-
duction of a test gene into the germ line of mice to create
transgenic animals allows the effects of the presence or absence
of cis-acting elements in the inserted transgene to be studied in
vivo. The transgene is fully integrated into chromatin and, if
sufficient DNA flanking the gene is included, all physiologic
aspects of transcriptional control theoretically can operate [137,
1381. Such a model is of particular use in studying developmen-
tal and tissue-specific gene expression, because simpler sys-
tems do not always accurately reflect these influences.
Semenza and colleagues have described human erythropoie-
tin gene expression in transgenic mice containing 4 different
human erythropoietin transgenes [134—1361; 3 transgenes con-
tained 0.7 kb of 3' sequence but differed at the 5' end in
containing 0.4 kb, 6 kb, and 14 kb of 5' flanking sequence. The
fourth transgene contained 16.5 kb of 5' sequence and 2.2kb of
3' sequence. The 0.4 kb transgene was widely expressed but
was inducible only in liver; the 6 kb transgi ne was inducibly
expressed in liver but was not expressed elsewhere; and the
longest two transgenes were expressed in an inducible manner
in the liver and kidney. This pattern led the authors to propose
the existence of an element between 0.4 kb and 6 kb that
represses expression in most tissues, and the existence of an
element between 6 and 14 kb that permits or controls renal gene
expression.
Such elements are believed to operate by binding tissue-
specific patterns of transcription factors that interact with
chromatin [for review see 139]. Interaction between bound
proteins over large distances probably occurs by bending of
DNA to permit direct protein-protein interactions [for review
see 128, 140]. Sequences themselves can bind inducible factors
or can operate permissively to control access of inducible
binding proteins at other sites [139, 141]. Thus, the absolute
requirement for a distant 5' sequence for renal expression but
not hepatic gene expression might imply the existence of
different mechanisms of gene control in these organs. Or the 5'
sequence simply might permit the operation of local sequences
in renal cells that are similar to those that operate in liver cells.
The achievement of erythropoietin tissue-specific gene ex-
pression in transgenic mice allows another approach to the
identification of the erythropoietin-producing cells. If an iden-
tifiable reporter gene is placed behind the erythropoietin pro-
moter, erythropoietin tissue-specific gene expression of the
reporter gene might be produced. The use of an oncogene as a
reporter might induce tumor formation and aid the setting up of
cell lines from specific tissues [142, 143]. One such oncogenic
product is the simian virus 40 large tumor antigen (SV4O T-
antigen). Using a 16.5 kb mouse erythropoietin construct con-
taining 9 kb of 5' erythropoietin sequence fused to the SV4O
T-antigen, my colleagues and I have produced several lines of
transgenic mice that show regulated expression of T-antigen in
the nuclei of a renal interstitial cell population (Fig. 6)1144].
Immunohistochemical detection of T-antigen in the nucleus can
be combined with detection of cytoplasmic antigens in double
labeling studies. These studies demonstrate co-localization with
5' ectonucleotidase in many of the interstitial cells, providing
strong evidence that it is the fibroblast-like renal interstitial cell
population that produces erythropoietin.
Definition of oxygen-inducible control elements in tissue
culture cells
In the absence of an appropriate renal cell line, two hepatoma
cell lines, Hep3B and HepG2, which show oxygen-regulated
erythropoietin gene expression [145], have been used widely for
tissue culture studies of erythropoietin gene regulation. These
experiments, together with studies using nucleoprotein extract
from whole kidney and liver, indicate that erythropoietin gene
control is probably the subject of several positive and negative
interactions mediated through DNA sequences in the promoter
[146—149], the 3' untranslated region [1501, and the sequence
lying just 3' to the poly A addition site [151—1531. To provide an
example of the definition and functional analysis of one of these
elements, I would like to describe the control sequence lying 3'
to the poly A addition site. To date, this is the most clearly
defined and powerful cis-acting sequence controlling oxygen-
regulated erythropoietin gene expression [151—153].
Transient transfection studies in human hepatoma cell lines
have been important in the functional definition of this element.
In this type of study, recombinant plasmid DNA containing the
sequence under investigation is introduced into cells by a
variety of techniques that permit DNA macromolecules to cross
cell membranes and enter the nucleus, where they can interact
with the nucleoproteins controlling gene transcription. Often a
reporter gene is fused to the cis-acting element under study to
provide a stable and easily measured product. Transfer of the
regulatory property to the heterologous reporter gene also
provides proof of independent operation of the control element
[for review see 154].
Beck et al used transient transfection of a shortened human
erythropoietin gene in Hep3B cells [1511. By making successive
deletions, they demonstrated that a sequence within a 150 bp
restriction fragment lying 120 bp 3' to the human erythropoietin
gene appeared to be responsible for mediation of the hypoxia-
inducible transcription. The region defined in these studies
corresponded with the 3' portion of a 256 bp region of DNA
shown by Semenza and colleagues to operate on the SV4O
promoter in transfected Hep3B cells [152]. In a similar analysis
of the mouse erythropoietin gene, using both a globin and the
ferritin gene as reporters, Pugh et al found the active sequence
to be located in an identical position 120 bp 3' to the mouse
erythropoietin gene [1531 (Figs. 7A and 7B). This sequence has
the classical features of a eukaryotic transcriptional enhancer in
operating independently of orientation and distance on a variety
of heterologous gene promoters. In addition to transducing
hypoxic responsiveness, it is also responsive to cobalt [1531,
thus mimicking the physiology of erythropoietin gene activation
and supporting the view that these stimuli interact on the same
signaling mechanism [122].
As expected for a functionally important sequence, a high
degree of homology between human and munne sequence was
observed. Although the sequence homology extends over at
least 140 bp, the minimal functional element required for
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Fig. 6. Photomicrograph of renal cortex from a transgenic
mouse expressing an erythropoietin SV4O T-antigen fusion gene
after anemic stimulation. Erythropoietin sequence was used to
direct expression of the viral oncogene T-antigen into the
erythropoietin-producing cells. Cells expressing the transgene
are demonstrated by immunoperoxidase using a rabbit antiserum
against T-antigen (arrows). These cells lie within the renal
interstitium. Additional double labeling studies (not shown)
indicate that they do not bear endothelial or leukocyte markers
but that a proportion express 5' ectonucleotidase (Maxwell PH,
Johnson M, Ratcliffe P, unpublished observations). They
correspond to the fibroblast-like type-I renal interstitial cells
[192].
enhancer activity in transiently transfected cells is shorter and
likely varies with the distance from the promoter on which it is
operating. Approximately 60—70 bp were necessary when the
enhancer element was placed 1.4 kb from an alpha globin
promoter [153], whereas a 43 bp sequence was sufficient for
enhancer function when placed close to the erythropoietin
promoter or close to a herpes simplex virus thymidine kinase
promoter [149]. The requirement for a more extensive DNA-
protein complex for operation at greater distances and in
chromatin is well established in other systems [139, 155]. It is
probable that the more extensive sequence homology in this
region indicates the need for more complex DNA-protein
interactions for the operation in this sequence in vivo from its
position 4 kb 3' of the erythropoietin gene promoter.
The structure of chromatin is altered at sites of gene expres-
sion, reflecting the binding of transcription factors. These
structural alterations change the sensitivity of the DNA to
chemical modification or cleavage by nucleases and result in
regions termed "hypersensitive sites." Thus important evi-
dence that this 3' enhancer does indeed function in vivo, at least
in liver, is provided by the demonstration of DNase I hyper-
sensitivity at this site in nuclei from liver [152]. More detailed
analysis of the exact position of the binding proteins in vivo
requires selection or amplification of the region of interest. This
technique, known as in-vivo footprinting [156], has not yet been
applied successfully to this sequence. However, nucleoproteins
that bind to this region have been detected by the more
commonly used in-vitro methods, in which nucleoprotein ex-
tract is bound in vitro to cloned DNA sequences. Bound
proteins can be detected by retardation of a labeled DNA probe
during electrophoresis. In addition, binding sites can be re-
vealed as areas of protection from chemical modification or
digestion by enzymes such as DNase I.
Using nucleoprotein extract prepared from Hep3B or HepG2
cells, an area of protection from DNase I digestion is observed
in both human [149, 157] and mouse sequences [158]; this area
lies within the minimal enhancer element defined in transfection
assays. This protected area contains a direct repeat of a
steroid/thyroid receptor-binding element half site. Blanchard
and colleagues demonstrated the functional importance of this
site by mutagenesis [149]. However, they were unable to
demonstrate modulation of hypoxic induction by glucocorti-
coids, thyroxine, or a variety of other known ligands for
members of this hormone receptor gene family. For many
members of this receptor family, known as orphan receptors,
the ligand is unidentified. The authors have proposed that such
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Fig. 7. Example of experiments
demonstrating cis-acting sequences that
convey oxygen-regulated gene expression in
transiently transfected tissue culture cells. A
Diagram of human a1 globin-mouse
erythropoietin fusion genes used to test mouse
erythropoietin sequences for ability to convey
oxygen regulation on the a globin reporter in
HepG2 cells. Restriction sites used in making
the deletions are indicated. Exons are marked
by stippling. B RNAse protection assay
showing reporter (alpha globin) and control
(FGH) plasmid expression after transient
transfection into HepG2 cells. Alternate lanes
show normoxic and hypoxic expression. The
erythropoietin gene fragments in the
constructs are indicated above each lane. An
ApaI-Pvu2 fragment lying at the 3' end of the
mouse erythropoietin gene (indicated by the
black box in A) is shown to convey
hypoxically induced expression independent
of distance or orientation and therefore to
contain a transcriptional enhancer (From Ref.
153).
a molecule might mediate hypoxic sensing. However, the
region identified in these DNase I protection studies does not
function as an oxygen-regulated enhancer in isolation, and
deletional analysis has demonstrated that a sequence extending
approximately 20 nucleotides 5' to this site is also necessary for
this action [149, 153, 157].
Mutational analysis of both the human [157] and mouse
sequence [158] is consistent with this region containing two
more distinct protein-binding sites. Furthermore, binding of a
hypoxic-induced nuclear factor to the most 5' of these sites has
recently been demonstrated by gel retardation assays (Fig. 8)
[157]. Thus the functional enhancer provides binding sites for at
least three DNA binding proteins. At present it is unclear
whether DNA binding proteins at all these sites interact with
the hypoxic sensing mechanism or whether the hypoxic modi-
fication is confined to one particular transcriptional factor, with
other proteins providing cooperative or permissive interactions.
One interesting aspect of this sequence, which has recently
been explored by Drs. Maxwell and Pugh working in my
laboratory, has been its oxygen-regulated operation when trans-
fected into a wide variety of tissue culture cells. These cells
include lines that do not make erythropoietin and are derived
from organs such as skin, lung, and ovary, organs that do not
contribute importantly to erythropoietin production in vivo
(Fig. 9) [159]. It is well known that nucleoprotein interactions
with transiently transfected DNA allow the promiscuous ex-
pression of tissue-specific genes. However, the demonstration
that transfected erythropoietin enhancer activity was inducible
by hypoxia n many different cells strongly suggests that a
physiologically relevant component of the oxygen-sensing
mechanism responsible for regulation of erythropoietin oper-
ates widely. The purpose of this widespread oxygen-sensing
mechanism is unknown, but it is possible that the same oxygen-
sensing system acts on other oxygen-responsive genes in cells
that are not specialized for the production of erythropoietin.
For erythropoietin regulation, the 10- to 15-fold induction of
transcription by the 3' enhancer is less than the 300-fold
changes in erythropoietin mRNA levels observed in vivo. This
observation implies the operation of other control mechanisms.
The 3' sequence could interact with other transcription control
elements to achieve much larger increases in the transcriptional
rate. Evidence for cooperation of this sort has recently been
obtained in Hep3B cells [149]. Transient transfection studies
demonstrated that combination of the 3' enhancer with the
erythropoietin promoter produced a cooperative interaction
capable of approximately 50-fold induction. Interestingly, se-
quence similarities were observed between the 3' enhancer and
the minimum inducible promoter.
Modulation of the steady-state levels of mRNA also could be
achieved through changes in the rate of degradation of the
mRNA superimposed on changes in the rate of gene transcrip-
tion. Evidence that both mechanisms operate to control eryth-
ropoietin mRNA levels has been obtained by comparison of the
amplitude of modulation of erythropoietin mRNA with direct
measurement of transcriptional rate by nuclear run-on experi-
ments [160]. Using nuclei from Hep3B cells, Goldberg and
colleagues estimated that the increase in transcriptional rate
during hypoxia was less than the increase in erythropoietin
mRNA, implying the occurrence of changes in erythropoietin
mRNA stability that are oxygen dependent. To demonstrate
this directly, mRNA half-life must be measured under varying
conditions of oxygenation. When Hep3B cells were switched
from a hypoxic to a normoxic environment, steady-state eryth-
ropoietin mRNA decreased by 50% within 1.5 to 2.0 hours.
Because new transcription was not blocked, this result repre-
sents a maximum estimate of the half-life in normoxic cells.
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lation is unclear. Thus hypoxia likely increases erythropoietin
mRNA stability in addition to activating transcription, but this
is as yet unproven.
Questions and answers
Fig. 8. Gel-shift assay identifying a DNA-binding activity to the human
erythropoierin 3' enhancer, which is induced by hypoxia. A Nucleotide
sequence of wild-type (W18) and mutant (M18) double-stranded oligonu-
cleotide probes. Nucleotides ito 18 from the hypoxia-inducible enhancer
are shown in uppercase letters, with the 3-nucleotide site of mutation in
M18 overlined and underlined. B Autoradiograph of a gei-shift assay
demonstrating binding of an induced nuclear factor to the wild-type but not
mutant probe. Nuclear extracts from Hep3B ceiis, cultured hypoxicaily
(+) or normoxically (—), were incubated with W18 probe, M18 probe, or
a control probe USF. The controi probe USF binds a constitutively
expressed factor and provides a control for normoxic and hypoxic extract
comparison. Several binding activities are observed and are labeled as
follows: N, nonspecific; C, constitutive; I, induced; U, USF; F, free
probe. Hypoxicaily inducible binding activity was demonstrated to the
wild type but not mutant probe. Specificity of this binding was shown in
other experiments by competition with unlabeled mutant and wild-type
probes (From Ref. 157).
However, when new transcription was blocked by actinomycin
D, the half-life of erythropoietin mRNA surprisingly increased
to approximately 8 hours and was, in fact, similar in normoxic
and hypoxic cells [1601. This effect of actinomycin D itself on
mRNA stability precluded measurement of the effect of oxy-
genation on mRNA stability by this method, but the finding is
itself of interest. Similar observations have been made with a
number of other genes [161, 1621 and have been interpreted as
indicating the existence of a specific ribonuclease that itself
turns over rapidly.
An element in the 3' untranslated region of erythropoietin
mRNA, which binds cytoplasmic proteins, has been identified
[163]. Although the binding activity of extract from brain was
inducible by hypoxia, inducibility was not seen in extracts from
liver or kidney, so the precise relation to erythropoietin regu-
DR. JOHN T. HARRINGTON (Chief of Medicine, Newton-
Wellesley Hospital, Newton, Massachusetts): Perhaps I could
start by asking about the evolutionary aspects of renal oxygen
sensing and erthropoietin production. Where in the phyloge-
netic tree does the renal tissue oxygen sensor appear?
DR. RATCLIFFE: This is an interesting question. A circulating
erythropoietic factor has been demonstrated by bioassay in a
large number of species, including birds, amphibians, and fish
[164—1661. However, there is no clear proof that these activities
are due to an erythropoietin; cross-reactivity with mammalian
erythropoietin is low or absent and, to my knowledge, biochem-
ical or genetic analysis has not been performed. In some ways
the responses resemble those of mammalian erythropoietin. For
instance, in a study in fish, plasma erythropoietic activity was
induced by bleeding but suppressed by starvation [166]. Nev-
ertheless, important differences have been observed. Frogs
produce an erythropoietic response to bleeding, but apparently
not to stimulation with cobaltous ions or hypoxic atmosphere,
and they do not become polycythemic during chronic hypoxia
[1641. Lack of polycythemia in chronic hypoxia also has been
reported in other cold-blooded species, such as turtles [1671. In
contrast, birds appear to respond similarly to mammals in that
they respond to both hypoxic atmosphere and to bleeding [165].
Whether this could indicate a different mechanism of oxygen
sensing and whether the difference might be a fundamental one
between cold-blooded and warm-blooded animals is unclear to
me.
As to the kidney itself as the site of oxygen sensing, I am not
aware of any evolutionary data. It is interesting, however, that
in certain fish and larval amphibia, the kidney is a significant
site of erythropoiesis with erythropoietic tissue lying between
mesonephric tubules [168].
DR. ADRIAN S. WOOLF (Lecturer, University College, Lon-
don Medical School, London, England): Is there any evidence
that in the chronically hypoxic normal kidney the erythropoie-
tin-producing cells proliferate?
DR. RATCLIFFE: In acute studies of rats and mice made
increasingly anemic, in-situ hybrization studies demonstrate the
rapid recruitment of what is almost certainly an existing popu-
lation of cells within the kidney [97]. I am not aware of any
in-situ hybridization studies in chronically anemic rodents that
securely answer the question as to whether proliferation of the
cells also occurs. Morphometric analysis of severely anemic
rats' kidneys, 8 days after induction of anemia by phenylhy-
dralazine and irradiation, has shown an increased interstitial
volume, an increase in the abundance of the processes of the
interstitial fibroblasts, and increased expression of 5' ectonu-
cleotidase by these cells [100]. However, mitoses were seldom
seen in these cells, even in very severely anemic animals.
Although this study did not examine erythropoietin production,
the transgenic work from my own group and recent in-situ
studies from others [941 indicate that it is this fibroblast-like cell
population that produces erythropoietin.
DR. JOHN E. SCOBLE (Consultant Nephrolo gist, Dulwich
Hospital, London): You suggested that the cells responsible for
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Fig. 9. Comparison of the activity of the
mouse erythropoietin 3' enhancer in different
cell types. Autoradiograph shows expression
of reporter (alpha globin) and control FGH
transcripts in transiently transfected human
cell lines Hep3B (hepatoma), U937
(monocyte/macrophage), MRC5 (lung
fibroblast), and IBR3 (skin fibroblast). In each
panel the first pair of lanes shows the
response when the reporter plasmid contained
the erythropoietin enhancer, and the second
pair shows the response when the reporter
plasmid did not contain the erythropoietin
enhancer. Induction of enhancer activity by
hypoxia is observed in all the cell types. Of
these cells, only the hepatoma cells express
the endogenous erythropoietin gene,
suggesting that the oxygen-sensing mechanism
might have other functions in the other cells
(From Ref. 159).
erythropoietin production are renal fibroblasts, and you com-
mented that renal fibroblasts grown in vitro do not produce
erythropoietin. Is it possible that these fibroblasts in vivo are
under some form of control by the cells surrounding them?
DR. RATCLIFFE: Yes, that is quite possible. Many unsuccess-
ful attempts have been made to obtain erythropoietin from
anatomically disrupted renal preparations. In contrast, in the
first 90 to 120 minutes of isolated renal perfusion, we have
observed up-regulation of erythropoietin mRNA that is similar
to that induced by anemia in vivo [1061. This paradox might be
explained if cellular cooperation were required for erythropoi-
etin production. Such a possibility also might provide a mech-
anism for loss of erythropoietin production in renal diseases,
where the intrarenal microenvironment is likely to be severely
disrupted.
DR. VICTORIA CATTELL (Senior Lecturer, Department of
Experimental Pathology, St. Mary's Hospital Medical School,
London): It has been suggested that the erythropoietin-produc-
ing cells might be peritubular capillary endothelial cells [92, 93].
These cells would be ideally sited for sensing the oxygen
content of blood. Also, the peritubular capillary obliteration in
chronic renal scarring might explain the loss of erythropoietin
production in chronic renal diseases. Can you be sure that the
erythropoietin-producing cells are not endothelial? Have you
performed any double-labeling immunohistochemical studies
with endothelial markers?
DR. RATCLIFFE: Using our Epo-Tag transgenic mice, we
attempted double-labeling studies with antiserum to T-antigen
and to factor VIII antigen. Unfortunately, whereas large vessels
stained well with factor VIII angtigen, interstitial capillary
staining was weak and our result was inconclusive. Recently
Dr. A. Vecchi and colleagues of the Mario Negri Institute in
Milan kindly gave us a rat monoclonal antibody to the murine
homologue of CD3 1. This antibody does stain the interstitial
capillary endothelium strongly; double-labeling studies with
this antibody indicate that the endothelial cell population is
distinct from the cell population expressing T-antigen in the
Epo-Tag mice. From this result we infer that erythropoietin
itself is not produced by the endothelium. Your remarks are
nevertheless very interesting; we cannot exclude the possibility
that the endothelium plays a role in oxygen sensing or that other
interactions with the endothelium are required for erythropoi-
etin production.
PROF. JOHN WALLS (Professor of Nephrology, Leicester
General Hospital, Leicester, England): You briefly mentioned
demand in connection with the relationship of oxygen supply
and blood supply within the kidney. Would you comment on
whether this is a sensing system for 02 concentration or
utilization in view of the observation that diuretics alter eryth-
ropoietin levels and that clinical states of hypoxia also are
associated with increased sodium reabsorption?
DR. RATCLIFFE: You mention an interesting point. I do not
know the answer to your question at the molecular level. An
oxygen sensor could respond directly to oxygen concentration
or to some consequence of oxygen utilization, so that both
possibilities are plausible, although the failure of cyanide to
mimic hypoxia [118—120] suggests that reduction in mitochon-
drial oxygen utilization is not the signal. At the level of the
cellular microenvironment, I think it is likely that oxyen
utilization by adjacent tissues such as the renal tubule is a
determinant of tissue oxygen concentration. Determination of
whether this is important in regulating erythropoietin produc-
tion will, I think, have to wait until we know more of the cellular
site and molecular mechanism of oxygen sensing in the kidney.
PROF. ANTHONY E. G. RAINE (Professor of Renal Medicine,
St. Bartholomew's Hospital, London): There are many re-
sponses to hypoxia other than those concerned with erythro-
poietin production, for example, hypoxic vasodilation. Is it
known whether the presumed oxygen sensor involved in these
situations is the same as that linked to production of erythro-
poietin?
DR. RATCLIFFE: The evidence for this is by no means
conclusive. For instance, expression of platelet-derived growth
factor 3 chain is increased by hypoxia in cultured endothelial
cells [169]. As with erythropoietin expression in hepatoma
cells, hypoxic induction is reduced by exposure to carbon
monoxide. So circumstantial evidence suggests that the mech-
anism might be similar. Another gene that shows hypoxic
induction with some similarities to erythropoietin gene expres-
sion is vascular endothelial growth factor [1701. Our demonstra-
tion that the erythropoietin 3' enhancer can interact with an
oxygen-sensing system in cell types that include endothelial
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cells would also be consistent with the possibility that a similar
mechanism might be involved, but we have as yet no direct
evidence for this. Another possibility is that a similar oxygen-
sensing mechanism might be involved in controlling glycolytic
and gluconeogenic capacity in liver [1711.
DR. JOHN DONOHOE (Consultant Nephrolo gist, Beaumont
Hospital, Dublin, Ireland): You showed data indicating a fairly
large potential for erythropoietin production in the liver. Might
there be ways of augmenting this extrarenal capacity in renal
failure?
DR. RATCLIFFE: Perhaps. It has long been recognized that
during regeneration following injury the potential for hepatic
erythropoietin production is increased. For instance, in one
study in rats, hepatic erythropoietin production in response to
hypoxia was increased about threefold during recovery from
partial hepatectomy when compared with that observed in
sham-hepatectomized animals [1721. The greatest erythropoie-
tin response was observed at the time of maximum cell prolif-
eration. However, I am unaware of any advances in our
understanding of this phenomenon that could lead to more
clinical methods of augmenting hepatic erythropoietin produc-
tion.
DR. HARRINOTON: Returning to erythropoiesis itself, perhaps
you could expand on what controls the expression of GATA- 1.
You moved on after calling it the master switch. I always like to
know what regulates a master switch.
DR. RATCLIFFE: The control of GATA-1, although currently
the subject of active research, is not clearly understood yet.
The GATA- 1 gene promoter contains GATA-binding sites that
are functional in erythroid tissues [173]; some type of autoreg-
ulatory response is likely, but that does not answer the question
as to what starts it all off.
DR. JOHN S. SAVILL (Weilcome Senior Fellow, Hammer-
smith Hospital, London): What types of molecules are candi-
dates for oxygen sensors? Are they likely to employ iron atoms
in a manner analogous to oxygen tra isport proteins?
DR. RATCLIFFE: That possibility is supported by the experi-
ments by Goldberg, Dunning, and Bunn on Hep3B, which I
outlined [122]. They have proposed the existence of a hemo-
protein sensor that reversibly ligands molecular oxygen. Such a
model is by no means proven, but there are examples of this
mechanism in other systems. For instance, fixL, which oper-
ates in control of the oxygen-sensitive nitrogen fixation genes of
Rhizobium meliloti, has recently been cloned, expressed, and
shown to be a hemoprotein operating in this way [123].
A great many other types of biochemical interactions with
oxygen could potentially provide sensing informaton, however.
Iron atoms can operate in a large variety of oxido-reduction
reactions. Redox systems, of course, would not necessarily
involve iron. For instance, recent studies indicate that the
DNA-binding activity of transcription factors such as AP- 1 and
NF-kB is subject to control by oxido-reduction status, and
Toledano and Leonard have proposed that reactions with
protein sulthydryl groups could mediate this change in activity
[174]. Unfortunately the list of candidate oxygen sensing mol-
ecules is not a short one.
DR. ANAND K. SAGGAR-MALIK (Research Fellow, St.
George's Hospital, London): Could you comment on what is
specific about polycystic kidney disease that allows erythropoi-
etin levels to be maintained compared to other renal diseases?
Can this model be used to study the oxygen-sensing mecha-
nism?
DR. RATCLIFFE: That is an interesting question. As I said,
within the cyst wall, it appears that stromal cells resembling
those identified in rodent kidneys contain erythropoietin mRNA
[23]. Why they should be able to function in that environment,
but less well in other anatomically disrupted kidneys, I do not
know. Interestingly, long-term dialysis patients can develop
acquired cystic disease and sometimes increase their hemato-
crit [175, 1761. This apparently erythropoietin-dependent re-
sponse [177] suggests that increased erythropoietin formation is
not related directly to the genetic defect but is in some way a
consequence of cyst formation. Perhaps this is simply a ques-
tion of local hypoxia arising from vascular distortion, but I
suspect it will be more complex and more interesting than that.
DR. CHARLES R. V. TOMSON (Consultant Nephrologist, St.
Bartholomew's Hospital): Would you comment on the possible
influence of the renin-angiotensin system on renal and extra-
renal erythropoietin production?
DR. RATCLIFFE: I can comment on some of the published
observations, but I cannot explain them. A number of early
studies demonstrated that infusion of angiotensin II could
increase erythropoietin as measured by bioassay [178, 1791,
although not all experiments showed this effect [180]. It is
tempting to suggest that angiotensin operates by inducing renal
hypoxia, but in one of these studies, to which I think you are
alluding, the effect was observed in nephrectomized animals.
This suggested that extrarenal production of erythropoietin also
might be augmented by angiotensin II [181]. More recentl' it
has been observed that angiotensin-converting-enzyme inhibi-
tors can ameliorate post-renal-transplant erythrocytosis [182,
183]. The coincident reduction in serum erythropoietin indi-
cates that the effect most probably is due to inhibition of
erythropoietin production [184]. Again, this might simply be
due to relief of renal hypoxia by vasodilation. It is nevertheless
puzzling that the source of erythropoietin in post-transplant
erythrocytosis appears most commonly to be the native kidneys
[185], where one might not expect well-preserved vascular
responses.
DR. DRAGAN LJUTICE (ISN Clinical Fellow, Guy's Hospital,
London): Is there any connection between erythropoietin pro-
duction and circulating hormones other than the renin-angio-
tensin system, specifically atrial natriuretic factor?
DR. RATCLIFFE: I am aware of published work on this, but I
would like to refer your question to Professor Raine, who has
worked on ANF for some time.
PROF. RAINE: Yes, a 1990 paper described increased eryth-
ropoietin production by human renal carcinoma cells in re-
sponse to atrial natriuretic factor [186]. Because supraphysio-
logic concentrations were used, the relevance of this finding to
erythropoietin production in vivo is uncertain. We have mea-
sured serum erythropoietin in a double-blind study in which we
administered ANF or placebo to renal transplant recipients, and
we saw no effect of ANF on serum erythropoietin [187].
DR. WOOLF: In view of the fact that a kidney (epithelial)
tumor cell line produces erythropoietin, what information is
known about erythropoietin production in the developing un-
differentiated kidney?
DR. RATCL!FFE: The developing kidney does produce eryth-
ropoietin [71], but! know of no studies that have established the
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cellular source of erythropoietin in the developing kidney, nor
how this cellular source might correlate with the process of
differentiation. Of course, erythropoietin production by Wilms'
tumor is a well-recognized phenomenon [188], but I am not at
all clear as to how this relates to erythropoietin production
during normal renal differentiation.
DR. CHRISTOPHER G. WINEARLS (Consultant Nephrologist,
Oxford, England): You drew our attention to the similarities
between erythropoietin and other growth factors. Do they also
act by preventing programmed cell death following liganding of
the receptor, as Dr. Bondurant recently suggested for erythro-
poietin?
DR. RATCLIFFE: That is the case, but perhaps I could ask Dr.
Savill to comment more specifically.
DR. SAVILL: Yes, apoptosis is activated in many systems
after withdrawal of growth factors, and these include other
hemopoietic lineages [189]. It may in fact be that separate
signals exist for preventing apoptosis and inducing cell prolif-
eration. Some evidence that this is the case with liganding of the
erythropoietin receptor and erythropoiesis has recently come
from the study of what appear to truncated forms of the
erythropoietin receptor [190]. In these experiments, cells trans-
fected with different forms of the erythropoietin receptor were
assessed for proliferative responses to erythropoietin. Trans-
fectants carrying the full-length erythropoietin receptor and
those carrying the truncated erythropoietin receptor prolifer-
ated equally in high concentrations of erythropoietin, but the
cells bearing the truncated erythropoietin receptor were more
susceptible to apoptosis. No difference between the transfec-
tants in the binding affinity for erythropoietin was observed,
and the authors have proposed that a distinct region of the
cytoplasmic portion of the erythropoietin receptor could be
responsible for signals that prevent apoptosis.
DR. HARRINGTON: Would you speculate on ways in which
the new information on the molecular biology of erythropoietin
might be applied to clinical medicine?
DR. RATCLIFFE: It is always difficult to predict the applica-
tion of advances in basic science, but I will try. Obviously we
hope that definition of the oxygen-sensing mechanism will have
medical applications way beyond the field of erythropoietin
itself, but it is far too early to consider what these might be.
Perhaps a more immediate possibility lies in further consider-
ation of the molecular interaction of erythropoietin with its
receptor. Such an interaction recently has been studied at the
crystallographic level for growth hormone and its receptor [49,
50]. This type of study could provide the basis for the design of
erythropoietic drugs that could be easier to administer or
cheaper to produce than erythropoietin itself.
Note added in proof
The hypoxically inducible DNA binding activity shown in Figure 8
has recently been demonstrated in multiple cell types [193, 1941 and
supports the functional demonstration of the widespread oxygen-
sensing system shown in Figure 9.
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